Results from Phase II Study Released by Bristol-Myers Squibb

Bristol-Myers Squibb Company introduced results from a Phase II study by which therapy having all-oral, dual direct-acting antiviral (DAA) schedule of daclatasvir, an investigational NS5A duplication involved inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, accomplished undetectable stream of traffic load 24 weeks post-treatment in 77% of difficult-to-treat genotype 1b hepatitis C affected individuals.

Difficult-to-treat affected individuals in this study added null responders, or affected individuals who might have had formerly not responded to therapy by using peginterferon alfa and ribavirin, and affected individuals who were scientifically unlikely or intolerance to preceding therapy by using alfa/RBV.

"Currently there exists no treatment options intended for hepatitis C genotype 1 that may be applied without having the concurrent use of alfa and ribavirin, which provides rise to a severe unmet need for individuals that are less likely or intolerance to alfa/ribavirin," said principal, Toranomon Hospital, Tokyo, Japan. "The results of this particularly Phase II study by using Bristol-Myers Squibb's daclatasvir and asunaprevir are favorable when we study potential hepatitis C therapies just for this difficult-to-treat affected person."